Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares jumped over 25% yesterday, leaving investors underwhelmed. The drug maker reaffirmed its 2016 financial guidance of revenues ranging from $9.9B to $10.1B and adjusted cash EPS ranging from $6.60 to $7.00, as it tries to restore investor confidence after facing a storm of criticism over its business practices.
However, Mizuho analyst Irina Rivkind Koffler remains unimpressed, noting, “…we don’t understand how the bottom line is feasible given the opex spending seen in the quarter. The company’s sales declined 12.6% Y/Y since the Salix acquisition has finally annualized and there is pressure from lower selling prices, generics, and divestitures, and we expect continued declines moving forward since the company can no longer employ significant price increases and faces increased generic competition for many of its “top 30″ products.”
Koffler reiterated an Underperform rating on shares of Valeant, with a price target of $11.00, which implies a downside of 60% from current levels.
Koffler is one of Valeant’s biggest bears, and she is also one of the top analysts rated who cover the stock. According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a yearly average return of 24.6% and a 60% success rate. Koffler has a 16.1% average return when recommending VRX, and is ranked #16 out of 4110 analysts.
Out of the 26 analysts polled by TipRanks, 8 rate Valeant Pharmaceuticals stock a Buy, 13 rate the stock a Hold and 5 recommend Sell. With a return potential of 121.5%, the stock’s consensus target price stands at $61.50.
Valeant shares are currently trading at $27.33, down $0.83 or -2.95%.